An Jie, Hu Yong-Guo, Cheng Kai, Li Cheng, Hou Xiao-Lin, Wang Gang-Lin, Zhang Xiao-Shuai, Liu Bo, Zhao Yuan-Di, Zhang Ming-Zhen
Britton Chance Center for Biomedical Photonics at Wuhan National Laboratory for Optoelectronics-Hubei Bioinformatics & Molecular Imaging Key Laboratory, Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, Hubei, PR China.
Britton Chance Center for Biomedical Photonics at Wuhan National Laboratory for Optoelectronics-Hubei Bioinformatics & Molecular Imaging Key Laboratory, Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, Hubei, PR China; Key Laboratory of Biomedical Photonics (HUST), Ministry of Education, Huazhong University of Science and Technology, Wuhan, 430074, Hubei, PR China.
Biomaterials. 2020 Mar;234:119761. doi: 10.1016/j.biomaterials.2020.119761. Epub 2020 Jan 6.
Nanocarrier for augmenting the efficacy of reactive oxygen species (ROS) by tumor microenvironment (TME) has become an emerging strategy for cancer treatment. Herein, a smart biodegradable drug delivery nanoplatform with mitochondrial-targeted ability, pH-responsive drug release and enzyme-like catalytic function is designed. This efficient ROS-generating platform uses ultrasound with deeper penetration capability as excitation source for combined chemotherapy and sonodynamic therapy (SDT) of tumor. In vitro experiments show that the nanoplatform can co-load Ce6 and DOX and be degraded in slight acid environment, and the DOX release rate is 63.91 ± 1.67%. In vivo experiments show that the nanoplatform has extremely biosafety and can be enriched in tumor site and excluded from body after 24 h. More significantly, after combined treatment, the tumors are eliminated and the mice still survive healthily without recurrence after 60 d. This is because not only it can achieve mitochondrial targeting and use platinum particle to increase oxygen content in TME to enhance the effect of SDT, but also it can use weak acidic TME to accelerate drug release to achieve the combination of chemotherapy and SDT. The probe provides a new strategy for designing ROS-based nanoplatform for the treatment of malignant tumor.
通过肿瘤微环境(TME)增强活性氧(ROS)疗效的纳米载体已成为一种新兴的癌症治疗策略。在此,设计了一种具有线粒体靶向能力、pH响应药物释放和类酶催化功能的智能可生物降解药物递送纳米平台。这个高效的ROS生成平台利用具有更深穿透能力的超声作为激发源,用于肿瘤的联合化疗和超声动力治疗(SDT)。体外实验表明,该纳米平台可以共负载Ce6和DOX,并在微酸性环境中降解,DOX释放率为63.91±1.67%。体内实验表明,该纳米平台具有极高的生物安全性,可在肿瘤部位富集,并在24小时后从体内排出。更显著的是,联合治疗后,肿瘤被消除,小鼠在60天后仍健康存活且无复发。这是因为它不仅可以实现线粒体靶向,并利用铂颗粒增加TME中的氧含量以增强SDT的效果,还可以利用弱酸性TME加速药物释放以实现化疗和SDT的联合。该探针为设计用于治疗恶性肿瘤的基于ROS的纳米平台提供了一种新策略。